BPC-157 10mg

BPC-157 (Body Protective Compound) is a synthetic 15-amino-acid peptide derived from a sequence originally identified in gastric juice. It is a stable pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that remains intact in aqueous and acidic conditions, making it a unique subject in peptide stability and bioavailability research.

Mechanism of Action

BPC-157 has been characterized in pre-clinical literature as interacting with the nitric oxide (NO) system and modulating growth factor expression, including VEGFR2-Akt-eNOS signaling. Published studies describe its influence on angiogenesis, fibroblast migration, collagen synthesis, and tendon outgrowth in vitro and in animal models.

Discovery & Context

First isolated and characterized in the early 1990s from a protective fragment of human gastric juice protein BPC. Since then, it has appeared in 100+ published pre-clinical papers across gastroenterology, orthopedics, and neuroscience research.

Published research literature covers the following areas:

• Angiogenesis and vascular repair
• Tendon / ligament tissue models
• Gastrointestinal barrier integrity
• Nitric oxide pathway modulation
• Growth factor (VEGF) signaling
• Muscle regeneration studies

LAR supplies this compound as a reference standard to qualified laboratories. No dosing schedules, administration methods, or human-use guidance is provided or implied.

1. Sikiric P. et al. (2018). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 24(18), 1990–2000. PubMed 29879879 ↗
2. Seiwerth S. et al. (2014). BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design, 20(7), 1126–1135. PubMed 23782146 ↗
3. Chang CH. et al. (2011). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 16(12), 10180–10192. Full text (PMC) ↗
4. Hsieh MJ. et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323–333. PubMed 27847966 ↗

Sealed vial: Stable at refrigerated temperatures (2–8 °C) for up to 24 months. Stable at room temperature (up to 25 °C) for 30 days during shipping.

After opening: Refrigerate at 2–8 °C and use within 30 days. Protect from light. Do not freeze after opening.

Visual check: Solution should remain clear. Discard if discoloration or precipitate appears.

Every batch is independently tested for purity, mass, and endotoxin load. Click any report to view the full analysis.